Skip to main content

sars-cov-2 mrna vaccine arct-021

Generic: SARS-CoV-2 mRNA Vaccine ARCT-021

sars-cov-2 mrna vaccine arct-021: 2 clinical trials tracked.

sars-cov-2 mrna vaccine arct-021 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about sars-cov-2 mrna vaccine arct-021, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

COVID-19

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (2)

A Phase 2, Multicenter, Double-Blind, Randomized, Controlled Trial of the Safety and Immunogenicity of a Self-Amplifying mRNA COVID-19 Vaccine in Adult Hematopoietic Cell Transplant Recipients

NCT07390968Registry updated 2026-02-09·Phase 2
Not yet recruiting

Primary endpoint: Geometric mean titer (GMT) of neutralizing antibody (nAb) against spike protein matching the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant

InterventionalRandomizeddouble56 targetStarted 2026-09Completion 2029-011 site · United StatesFred Hutchinson Cancer Center

A Phase 1/2 Randomized, Observer-Blind Study of the Safety, Reactogenicity, and Immunogenicity of 3 SARS-CoV-2 RNA Vaccine Candidates in Adults Previously Vaccinated and Not Previously Vaccinated Against SARS-CoV-2

NCT05037097Registry updated 2025-10-15·Phase 1
Completed

Primary endpoint: Number of Participants Reporting Solicited Local or Systemic Adverse Events (AEs)

InterventionalRandomizedquadruple72 enrolledStarted 2021-08Completion 2023-124 sites · Singapore, South Africa, United StatesArcturus Therapeutics, Inc.